The Great Place to Work institute, an impartial and widely respected authority on workplace culture, has certified Hansa Biopharma AB as a Great Place to Work 2022, the pioneer in enzyme technology for rare immunological disorders. Hansa has already been certified three times in a row.
The Great Place to Work survey, which was completed by 99% of participants, reveals consistent improvement over time, with particularly high scores in areas relating to pride in work accomplished and its effect on the community, a sense of belonging and dedication, and the perception that people are treated with respect and fairness and can be themselves in the workplace.
“We are very encouraged by this third consecutive certification of Hansa as a Great Place to Work. This achievement reflects the high level of commitment and dedication of our employees during the transformation of Hansa into a fully integrated, commercial-stage biopharmaceutical company. Every year we carefully evaluate the results and feedback we receive from this survey and based on this we implement appropriate initiatives team by team and across the entire organization. Our goal is to shape Hansa to be a uniquely inspiring and rewarding workplace and this third consecutive certification indicates how far we have come”
Anne Säfström Lanner, SVP & CHRO
The leading expert on workplace culture is Great Place to Work. They have polled over 100 million workers globally since 1992 and utilised the results to define what makes a great workplace. Their benchmark data is utilised to identify Great Place to Work-Certified businesses and the Best Workplaces in more than 60 countries, including the 100 Best Companies to Work For and World’s Best lists that Fortune publishes each year.
- Award granted by internationally recognized Great Place to Work institute.
- Certification based on company-wide survey completed by 99% of Hansa employees.
- Metrics related to trust in the company, credibility, pride and fairness, continue to be among those most highly rated by employees.
